CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions
Mengying Guan, Hua Hao · 2026
Read CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions by Mengying Guan, Hua Hao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13465125.txt.
Description
Mengying Guan and Hua Hao review CDK4/6 blocker drugs in hormone-driven breast cancer, where the drugs have redrawn the treatment map. Three drugs in the class serve both early and spread disease. The review weighs them side by side rather than as interchangeable copies.
Real gaps in benefit appear between the three drugs across trial settings. Resistance grows through two broad routes: loss of the drug's target machinery, or detours that bypass the block entirely. Sorting resistance that way can guide what to try next, the authors argue. Protein shredders, new hormone blockers, and antibody-guided drugs lead the next wave. Sharper patient picking may gain more than yet more drugs, they conclude.
Catalog record
| CREATOR | Mengying Guan, Hua Hao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |